Last reviewed · How we verify
NCT03573375
Barriers Affecting Physical Activity
NA trial testing Questionnaires in Cancer Patients and Physical Activity in 200 participants. Completed in 12 November 2021.
12 November 2021
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 200 |
| Start date | 20 June 2018 |
| Primary completion | 12 November 2021 |
| Estimated completion | 12 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Questionnaires
Conditions studied
- Cancer Patients and Physical Activity — all drugs for Cancer Patients and Physical Activity →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Cancer Patients and Physical Activity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this research study is learn about how often cancer patients engage in physical activity using the exercise behavior questionnaire. This is an investigational study. Up to 200 participants will be enrolled in this study. All will take part at MD Anderson.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03573375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaires
Trials testing the same drug.
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07499518 — Fertility and Polycystic Ovary Syndrome · not yet recruiting
- NCT07487844 — Pulsed Electric Field Ablation for Metastatic Breast Cancer · NA · not yet recruiting
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT06836414 — Lung Cancer Screening CT for Firefighters · NA · withdrawn
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03573375 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03573375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing